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Lisa Honeyman1†, Mark Bazett1†, Tomasz G Tomko1 and Christina K Haston2*Abstract
Background: Idiopathic pulmonary fibrosis is a disease characterized by alveolar epithelial cell injury, inflammatory
cell infiltration and deposition of extracellular matrix in lung tissue. As mouse models of bleomycin-induced
pulmonary fibrosis display many of the same phenotypes observed in patients with idiopathic pulmonary fibrosis,
they have been used to study various aspects of the disease, including altered expression of microRNAs.
Results: In this work, microRNA expression profiling of the lungs from treated C57BL/6J mice, relative to that of
untreated controls, was undertaken to determine which alterations in microRNAs could in part regulate the
fibrosis phenotype induced by bleomycin delivered through mini-osmotic pumps. We identified 11 microRNAs,
including miR-21 and miR-34a, to be significantly differentially expressed (P < 0.01) in lungs of bleomycin treated
mice and confirmed these data with real time PCR measurements. In situ hybridization of both miR-21 and
miR-34a indicated that they were expressed in alveolar macrophages. Using a previously reported gene expression
profile, we identified 195 genes to be both predicted targets of the 11 microRNAs and of altered expression in
bleomycin-induced lung disease of C57BL/6J mice. Pathway analysis with these 195 genes indicated that
altered microRNA expression may be associated with hepatocyte growth factor signaling, cholecystokinin/
gastrin-mediated signaling, and insulin-like growth factor (IGF-1) signaling, among others, in fibrotic lung disease.
The relevance of the IGF-1 pathway in this model was then demonstrated by showing lung tissue of bleomycin
treated C57BL/6J mice had increased expression of Igf1 and that increased numbers of Igf-1 positive cells,
predominantly in macrophages, were detected in the lungs.
Conclusions: We conclude that altered microRNA expression in macrophages is a feature which putatively
influences the insulin-like growth factor signaling component of bleomycin-induced pulmonary fibrosis.
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Idiopathic pulmonary fibrosis (IPF) is a progressive disease
of the lung interstitium characterized by deposition of
extracellular matrix, inflammatory cell infiltration, and
fibroblast recruitment and hyperplasia which leads to im-
paired lung function and ultimately, respiratory failure
[1,2]. While the etiology of IPF is unknown, many of the
characteristics of this disease are mimicked by the mouse
models of bleomycin-induced pulmonary fibrosis [2,3].* Correspondence: christina.haston@mcgill.ca
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distribution, and reproduction in any mediumMice treated with bleomycin display subpleural scarring
characterized by cellular inflammatory cell infiltration and
extracellular matrix deposition in the alveoli, as has been
described in clinical cases of idiopathic pulmonary fibrosis
[2,3]. Studies have shown bleomycin-induced pulmonary
fibrosis is influenced by, among others, secretion of a var-
iety of chemokines [4,5], recruitment of inflammatory cells
[6], involvement of transforming growth factor β1 (TGF-
β1) [7,8] and epithelial-mesenchymal transition [9].
Many of the subphenotypes involved in bleomycin-
induced pulmonary fibrosis have been shown to be
independently influenced by microRNAs, including in-
flammation [10], tissue repair [11,12], cell differentiation
[13,14] and cell proliferation [15]. MicroRNAs are smalltral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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Figure 1 Bleomycin-induced pulmonary fibrosis phenotype of
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tides that regulate gene expression through complimentary
binding, usually to the 3′-untranslated region of target
mRNAs. MicroRNAs reduce gene expression by causing
disruption of mRNA stability or translation [16-18] and
can significantly change cellular processes through both
repression of important targets and repression of mul-
tiple targets within the same pathway/process [19]. A
large number of pathologies are known to be influenced
by microRNAs. For respiratory diseases these include
cancer [20], asthma [21], chronic obstructive pulmonary
disease [22], cystic fibrosis [23] and idiopathic pulmon-
ary fibrosis [24-26].
Others have investigated the involvement of microRNAs
in the development of bleomycin-induced pulmonary fi-
brosis using intratracheal [27-29] and intraperitoneal [30]
treatment delivery models. Among those microRNAs pre-
viously shown to be perturbed in fibrosis are microRNA-
21 (miR-21) [29], miR-29 [30], miR-200 [31], miR-154
[24], miR-199a-5p [28] and let-7d [26]. These microRNAs
have been shown to affect the epithelial-mesenchymal
transition [25,31] and are expressed in fibroblasts [28] and
myofibroblasts [29,30]. A mini-osmotic pump model of
bleomycin-induced pulmonary fibrosis has been shown to
more appropriately model the human disease [3,32] but
the contributions of microRNA to the development of the
pulmonary fibrosis phenotype have not been investigated
using this model.
In this report, we use a mini-osmotic pump model
of bleomycin-induced pulmonary fibrosis to investi-
gate whether unique microRNAs contribute to the ob-
served phenotypic changes. We initially measured the
microRNA signature of the lung tissue with a micro-
array, and evaluated the cellular site of expression of
specific microRNAs. Through bioinformatic analyses
of genes potentially regulated by the differentially
expressed microRNAs, coupled with a documented
gene expression profile [33], we identified putative
biological functions and pathways, including insulin-
like growth factor signaling, through which these
microRNAs may affect the bleomycin-induced lung
response.C57BL/6J mice. Mice were exposed to 100 U/kg of bleomycin
through a mini-osmotic pump and euthanized six weeks later.
Control mice were not treated. Images of left lung histological
sections stained with Masson’s trichrome; magnification 100×.
(A) C57BL/6J with regions of subpleural pulmonary fibrosis, as
indicated by the blue collagen streaks. (B) C57BL/6J control.
(C) Average fibrosis ± standard deviation of n = 3 mice per group.Results
Bleomycin-induced lung phenotype
Bleomycin treatment by mini-osmotic pump produced a
pulmonary fibrosis in C57BL/6J mice consisting of re-
gions of subpleural atelectasis, at six weeks post treat-
ment, as shown in Figure 1A, which is consistent with
previous reports of this model [3,33,34]. On average, the
fibrotic scar covered 5.9 ± 1.8% of the lung in bleomycin
treated C57BL/6J mice, while fibrosis was not evident in
untreated control mice, as shown in Figure 1.MicroRNAs are differentially expressed in the bleomycin
treated mouse lung
To determine whether the microRNA expression profile
was altered in the fibrotic lung, we harvested lung tissue
from mice six weeks after bleomycin treatment and from
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microRNA expression levels. As shown in Figure 2, 11
microRNAs were differentially expressed (false discovery
rate (FDR) < 0.01) between these groups, and the expres-
sion values of these microRNAs in lung tissue segregated
the samples from fibrotic and control mice. Three mic-
roRNAs had decreased expression in the bleomycin
treated lungs (miR-26a, miR-151-3p and miR-676) while
eight microRNAs had increased expression in the bleo-
mycin treated lungs (miR-146b, miR-199a-5p, miR-21,
miR-34a, miR-335-5p, miR-207, miR-301a and miR-449a).
To verify the differentially expressed microRNA identi-
fied by microarray, we completed a quantitative RT-PCR
assessment of miR-21, miR-34a, miR-355-5p, and miR-26a
using lung RNA from biological replicates for mice six
weeks after bleomycin treatment and for control mice, as
shown in Figure 2B. When comparing bleomycin treated
levels to control, miR-21 (P = 0.009), miR-34a (P = 0.015)
and miR-355-5p (P = 0.07) were all increased, while miR-
26a (P = 0.04) was decreased, confirming the microarray
results. To determine whether these microRNAs were of
altered expression earlier in the development of the pheno-
type, we completed quantitative RT-PCR on samples pro-
cured from mice at the three week timepoint. As seen in
Figure 2C, miR-21, miR-34a and miR-355-5p were all sig-
nificantly increased compared to controls, while miR-26a
was not significantly decreased at this earlier timepoint.
In situ hybridization was conducted to histologically as-
sess the levels of miR-21 and miR-34a in the lungs of mice
at six weeks after bleomycin treatment and in control
mice. As shown in Figure 3, the numbers of each of miR-
21 and miR-34a positive cells were significantly increased
in the lungs of bleomycin treated mice as compared to
controls. The majority of miR-21 and miR-34a positive
cells were within the alveolar space and were morpho-
logically identified as macrophages, as seen in the magni-
fied inserts. Further, immunohistochemical staining of the
lungs of bleomycin treated and control animals showed an
increase in F4/80 positive cells (macrophages) within the
alveolar space at six weeks following bleomycin treatment,
which corresponded to the increase in miR-21 and miR-
34a positive cells (Additional file 1).
Functional analysis of microRNA targets
To evaluate the potential biological consequence of the
differentially expressed pattern of microRNAs in fibrotic
lung tissue, we initially compiled a list of genes predicted
to be regulated by the significantly differentially expressed
microRNAs (n = 11; Figure 2) by TargetScan. In addition,
we had previously measured the gene expression profile of
bleomycin-induced pulmonary fibrosis in C57BL/6J mice
also using mini-osmotic pumps, and evaluated at six
weeks [33]. An assessment of the extent of overlap of
these predicted targets with the measured signature ofdifferentially expressed genes revealed 195 of the 2,527
predicted target genes to be common, and in the correct
orientation, with genes which were differentially expressed
in the lungs of bleomycin treated mice (n = 1,954). The
overlap was considered to be in the correct orientation
when a gene targeted by an upregulated microRNA was
decreased in the gene expression profile, or when a gene
targeted by a downregulated microRNA was increased in
the gene expression profile.
Pathway analysis of the 195 genes that were predicted
targets of the microRNAs and present in the gene expres-
sion analysis revealed that microRNAs potentially affect,
among others, hepatocyte growth factor (HGF) signaling,
insulin-like growth factor 1 (IGF-1) signaling and molecu-
lar mechanisms of cancer pathways in bleomycin-induced
pulmonary fibrosis (Table 1). Genes that had altered ex-
pression but were not predicted to be influenced by
microRNA levels were prominent in pathways including
granulocyte adhesion and diapedesis, complement system
and production of nitric oxide and reactive oxygen species
in macrophages (Additional file 2).
To investigate whether the IGF-1 signaling pathway
was altered in this model of bleomycin-induced lung dis-
ease, we assayed the expression of IGF family members
in lung with qRT-PCR and immunohistochemistry. As
shown in Figure 4, both Igf-1 and Igfbp5 were signifi-
cantly increased in lung tissue from mice at six weeks
after bleomycin treatment when compared to control,
while Igfbp3 was significantly decreased. Supporting this,
the number of Igf-1 positive cells was significantly in-
creased in pulmonary tissue from bleomycin treated
mice. The Igf-1 positive cells were morphologically con-
sistent with macrophages.
Discussion
In this study, we provide evidence for a set of microRNAs
which are of altered expression in pulmonary tissue of
mice challenged with bleomycin by mini-osmotic pump,
and we specifically show miR-21 and miR-34a to be pre-
dominately expressed in lung macrophages in this model
of pulmonary fibrosis. Secondly, through bioinformatic
analysis of the predicted targets and of genes known to
have altered expression in bleomycin treated mice, path-
ways through which the microRNAs could affect lung dis-
ease were revealed. Among these we identified the IGF-1
pathway as putatively regulated by microRNAs in lung fi-
brosis and showed that numbers of Igf-1 positive cells,
also macrophages, were increased in the lungs of bleo-
mycin treated mice.
Through expression profiling, we identified 11 mic-
roRNAs to be differentially expressed in the lungs of mice
presenting bleomycin-induced pulmonary fibrosis com-
pared to lungs from untreated control mice and of these











































































Figure 2 Pulmonary microRNA profile of bleomycin treated and
control C57BL/6J mice. Mice were treated with 100 U/kg
bleomycin through mini-osmotic pumps and lung tissue harvested
three or six weeks later. (A) 11 microRNA were identified as being
differentially expressed (FDR < 0.01) in lung clustering the treated
and control mice separately. Relative expression is log2 transformed.
Yellow indicates over expression, blue indicates under expression
compared to a reference expression level. N = 3 mice per group.
(B) MicroRNA expression in the lungs of bleomycin treated at six
weeks and control mice, relative to the U6 control, was assessed by
qRT-PCR. (C) MicroRNA expression in the lungs of bleomycin treated
at three weeks and control mice, relative to U6 control, was assessed
by qRT-PCR. Average ± standard deviation of n = 5 to 8 mice per
group. * indicates a significant difference between groups, P < 0.05.
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mice 7 and 21 days following exposure to intratracheal
bleomycin and among the microRNAs of altered expres-
sion were increased levels of miR-21, miR-34a and de-
creased levels of miR-26a, in concordance with our data.
Using a model of intraperitoneal delivery of bleomycin,
Cushing et al. [30] reported the altered expression of add-
itional microRNAs common to the present work, miR-
449a and miR-146b, further to their evidence of miR-21,
miR-34a within the fibrosis microRNA profile at 10 and 28
days following bleomycin administration. Finally, Lino
Cardenas et al. [28] showed these four microRNAs, as well
as miR-199a-5p to be among the microRNAs differentially
expressed in the lungs of mice which developed fibrosis 14
days after intratracheal bleomycin instillation. Further work
in each of these studies demonstrated specific microRNAs
(mir-21, mir-29 and mir-199a-5p) to be expressed in myo-
fibroblasts, and to affect TGF-β signaling and fibroblast
function, leading to fibrosis development.
Our findings which indicate miR-21 and miR-34a to be
predominantly expressed in macrophages, a significant in-
flammatory component of our model [32], and others [30]
suggest that microRNA regulation of inflammation may
be important in the pathology of pulmonary fibrosis.
Supporting these data, Lu et al. [21] also detected miR-21
as being expressed in pulmonary macrophages of A.
fumigatus-challenged mice and in a survey of expression,
the levels of miR-21 in macrophages exceeded that of epi-
thelial or fibroblast cell lines. Secondly, Vaporidi et al. [35]
reported miR-21 to be expressed in macrophages in a
mouse model of ventilator-induced lung injury.
The profile of differentially expressed microRNAs in
this model of bleomycin-induced lung disease includes
specific microRNAs which have been functionally impli-
cated in mechanisms of relevance to fibrosis develop-
ment. For example, miR-34a has been shown to regulate
cardiac function and ageing, in part through affecting
fibrosis in this tissue [36] and miR-26a can also affect
cardiac fibrosis through altering collagen I levels [37].
























Figure 3 Pulmonary expression of miR-21 and miR-34a in bleomycin treated and control C57BL/6J mice. Mice were treated with100 U/kg
bleomycin through mini-osmotic pumps and lung tissue harvested six weeks later. In situ hybridization of miR-21 in (A) bleomycin treated lungs
and (B) control lungs. In situ hybridization of miR-34a in (C) bleomycin treated lungs and (D) control lungs. (E) In situ hybridization using a
scrambled probe as a negative control. No positive cells were identified when using the scrambled probe in control or bleomycin treated lungs.
Magnification 400×, insert magnification 1000×. (F) Quantification of 10 random fields per lung for miR-21 and miR-34a positive cells per mm2 ±
standard deviation of n = 4 to 9 mice per group. * indicates a significance difference between groups, P < 0.005.
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a model of intestinal epithelial cell differentiation. Finally,
miR-301a was demonstrated to contribute to T helper
type 17 cell development in a model of autoimmune en-
cephalomyelitis [40], and thus could function to alter this
lymphocyte of importance to pulmonary fibrosis path-
ology [41].
The analysis of the bleomycin-induced pulmonary fibro-
sis gene expression profile, combined with that of the in-
duced changes in pulmonary microRNA levels, revealed
novel pathways through which pulmonary fibrosis may de-
velop in this model. In particular, microRNA regulation of
genes of hepatocyte growth factor-, endothelin-1- or IGF1-
signaling, and specific molecular mechanisms of cancer,may affect lung fibrosis. Using the combined microRNA-
mRNA approach employed here, Dong et al. [42] impli-
cated mir-29 mediated effects on the cell cycle and
on cell adhesion, among other processes, to influence
bronchopulmonary dysplasia in mice. Secondly, using this
type of analysis, Ezzie et al. [22] revealed that microRNA
regulation of transforming growth factor β, Wnt and focal
adhesion pathways may be relevant to the development of
clinical chronic obstructive pulmonary disease.
IGF-1 signaling was among the pathways revealed in the
gene expression analysis and there is both clinical [43,44]
and experimental [45,46] evidence that perturbations of
IGF signaling could contribute to IPF. Specifically, in-
creased IGF-1 [43] and IGFBP5 [44] levels were reported
Table 1 Pathways represented within the microRNA targets common to the set of bleomycin-induced genes
Ingenuity canonical pathway Minus log (P-value) Molecules
Axonal guidance signaling 4.5 EPHA7, ARHGEF12,SOS2,PTCH1,ITGA5,ROBO1,WNT2,
EFNB2,FZD4,IGF1,EFNB1,GNA13,PRKD3,ADAM9,NRP1
Role of NANOG in mammalian embryonic stem cell pluripotency 3.65 SOX2,LIF,FZD4,GAB1,SOS2,BMPR2,WNT2
HGF signaling 3.07 ETS1,GAB1,SOS2,MAPK10,ETS2,PRKD3
Cholecystokinin/gastrin-mediated signaling 3.02 ITPR2,SOS2,MAPK10,RHOU,GNA13,PRKD3
Pantothenate and CoA biosynthesis 2.93 PANK1,ENPP1,ENPP5
Molecular mechanisms of cancer 2.82 ARHGEF12,FZD4,GAB1,SOS2,PTCH1,MAPK10,RHOU,
BMPR2,HIF1A,GNA13,PRKD3
Endothelin-1 signaling 2.56 EDNRB,GAB1,ITPR2,MAPK10,MAPK6,GNA13,PRKD3
RAR activation 2.49 TAF4 RARB,IGFBP3,MAPK10,NCOR1,PRKD3,PPARGC1A
Mouse embryonic stem Cell pluripotency 2.37 SOX2,LIF,FZD4,SOS2,BMPR2
Phospholipase C signaling 2.35 ARHGEF12,ITPR2,SOS2,RHOU,RPS6KA3,ITGA5,GNA13,PRKD3
IGF-1 signaling 2.31 CTGF,IGF1,SOS2,IGFBP3,GRB10
Hepatic fibrosis/hepatic stellate cell activation 2.31 COL1A2,CTGF,IGF1,EDNRB,FLT1,IGFBP3
ERK5 signaling 2.29 LIF,GAB1,RPS6KA3,GNA13
Glioblastoma multiforme signaling 2.17 FZD4,IGF1,ITPR2,SOS2,RHOU,WNT2
Growth hormone signaling 2.15 IGF1,IGFBP3,RPS6KA3,PRKD3
GDNF family ligand-receptor interactions 2.15 GAB1,ITPR2,SOS2,MAPK10
Renal cell carcinoma signaling 2.11 ETS1,GAB1,SOS2,HIF1A
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and Uh et al. [47] demonstrated macrophages to be the
important source of IGF in IPF, which is consistent with
the findings of our model. IGFBP3, which has decreased
mRNA expression in our model, has been shown to be in-
creased in patients with IPF in both bronchoalveolar lav-
age [43] and lung tissue [44], indicating that some
components of the IGF1 pathway differ between human
IPF and our model. Experimentally, Andronegui et al. [45]
have shown adenoviral treatment of mice with both Igf
and Tgf-β to increase pulmonary fibrosis over mice receiv-
ing Tgf-β alone, while Yasuoka et al. [46] demonstrated
adenoviral treatment with Igfbp5 to have the same effect,
thus directly implicating the IGF-1 pathway in fibrosis
development. Ruan and Ying [48] suggest that this change
in IGF binding proteins could be an initiating factor in IPF
and Veraldi and Feghali-Bostwick [49] propose IGF bind-
ing proteins to be central mediators of fibrosis. Our
findings, indicting the IGF pathway to be significantly rep-
resented in microRNA regulation of bleomycin-induced
pulmonary fibrosis, coupled with increased Igf-1 levels in
fibrotic lung tissue, support this line of investigation and
suggest the involvement of microRNA regulation.
As by definition, the cause of idiopathic pulmonary fibro-
sis (IPF) is unknown, developing an animal model which
accurately represents the disease has proven to be difficult
[50]. Several methods exist to induce pulmonary fibrosis in
rodents including modulation of gene expression usingviral vectors or transgenic animals or administration
of agents such as bleomycin, fluorescein isothiocyanate
(FITC), silica, and irradiation [50,51]. Each of these models
has strengths, but the majority fail to reproduce the
chronic nature of IPF [50]. Despite limitations, bleomycin-
induced fibrosis remains the most widely used and is con-
sidered to be the best model for the study of IPF [51,52].
There are many routes of bleomycin administration used
in animal models including intratracheal, intravenous, in-
traperitoneal, or subcutaneous and each of these produces
fibrosis at a different time point following treatment. While
single doses of bleomycin are often sufficient to induce fi-
brosis, models that involve repeated or prolonged bleo-
mycin exposure, such as our mini-osmotic pump, are
considered improved [50,51] as they result in progressive
fibrosis which more closely mimics IPF [3,32]. A limitation
associated with this approach is the fact that the presence
of the pump itself may affect the lung, and although we
have shown that saline filled pumps do not produce pul-
monary fibrosis in mice [53] we can not exclude an effect
of the pumps on microRNA expression in this model.
Conclusions
In conclusion, using microRNA profiling of a mini-
osmotic pump model of bleomycin-induced pulmonary
fibrosis, combined with gene expression profiling data,
we have identified that microRNAs putatively affect
the IGF-1 pathway in pulmonary fibrosis. Further, the
A B
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Figure 4 Pulmonary expression of IGF-1 pathway genes in bleomycin treated and control C57BL/6J mice. Immunohistochemistry of Igf1
in (A) bleomycin treated lungs and (B) control lungs. Magnification 400×, insert magnification 1000×. (C) Quantification of Igf-1 positive cells per
mm2 lung tissue ± standard deviation of n = 4 mice per group. (D) qRT-PCR of lung tissue from bleomycin treated and control mice for genes of
the IGF-1 pathway. Expression is relative to reference gene Ataxin 10. Average ± standard deviation of n = 6 to 8 mice per group. * indicates a
significant difference between groups, P < 0.05.
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phages suggests microRNA regulation of the inflamma-
tory response may contribute to the development of
pulmonary fibrosis in this model.
Methods
Mice, bleomycin treatment and fibrosis phenotyping
C57BL/6J mice were purchased from the Jackson Labora-
tory (Bar Harbor, ME, USA) and housed at the Meakins-
Christie Laboratories. At eight weeks of age, the mice were
treated with 100 Units/kg bleomycin sulphate (Mayne
Parma, Montreal, QC, Canada) dissolved in saline, through
mini-osmotic pumps (Alzet 2001, Cupertina, CA, USA) as
in past studies [33,34]. Untreated mice were assessed as
controls. At three or six weeks post treatment, the mice
were euthanized by sodium pentobarbital overdose. The
right lung was immediately homogenized in TRI Reagent
(Sigma, Oakville, ON, Canada) and stored at −80°C until
RNA isolation [54,55]. The left lung of each mouse was
perfused with 10% neutral buffered formalin and submitted
for histological processing. Lung sections were stained with
Masson’s trichrome to identify the area of collagen depos-
ition in the lung which were determined from user-drawn
regions and compared to the area of the entire lobe
(Image-Pro Plus Software, Rockville, MD, USA) to generatethe per cent fibrosis in the lung as in previous studies [53].
Animal experiments were completed under a protocol ap-
proved by the McGill University Animal Care Committee
in agreement with the guidelines of the Canadian Council
on Animal Care.
RNA isolation and microarray
Total RNA from the lungs of three bleomycin treated ani-
mals and three untreated animals was isolated using
miRNeasy Mini kits according to the manufacturer’s proto-
col (Qiagen, Germantown, MD, USA). Exiqon (Vedbaek,
Denmark) performed target preparation and array hy-
bridization according to their protocol. In short, 1 μg of
total RNA from sample and reference was fluorescently la-
beled with Hy3 or Hy5 respectively and hybridized to a
miRCURY LNA array version 11.0 (Exiqon, Vedbaek,
Denmark) containing probes for all mouse microRNAs
registered in miRBASE (version 12) [56]. 598 microRNA
probes were assessed in quadruplicate with hybridization
being performed on a Tecan HS480 hybridization station
(Tecan, Männedorf, Switzerland). Slides were scanned
using an Agilent G2565BA Microarray Scanner System
(Agilent Technologies, Inc., Mississagauga, ON, Canada)
and image analysis was carried out using ImaGene 8.0 soft-
ware (BioDiscovery, Inc., Hawthorne, CA, USA). Data were
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Lowess (LOcally WEighted Scatterplot Smoothing) regres-
sion algorithm [57]. Differential microRNA expression be-
tween bleomycin treated and control tissue was determined
by Student’s two-tailed t-tests with P < 0.01 after FDR (false
discovery rate) correction for multiple testing. The dataset
was deposited into Genome Expression Omnibus (GEO;
accession number GSE45789).
Gene expression profile
Using previously published microarray data (GDS1492,
[33]), the differential gene expression profile between
bleomycin treated and control lung tissue was deter-
mined by Cyber-T test [58] with P < 0.01 after FDR cor-
rection for multiple testing.
MicroRNA target prediction and pathway analysis
Predicted targets for the 11 significantly differentially
expressed microRNAs were identified using TargetScan
Human 6.0 [59]. This database predicts mouse genes
using orthologs to human annotation owing to the im-
proved documentation of the 3′-untranslated region of
human genes. The gene expression profile of bleomycin-
induced pulmonary fibrosis was previously published
(GDS1492, [33]) and we filtered the genes from this list
to determine gene expression that had an inverse rela-
tionship with microRNA expression levels.
Pathway analysis was completed by uploading gene lists
into the Ingenuity Pathway Analysis program (Ingenuity®
Systems, Redwood, CA, USA) and identifying the signifi-
cant pathways represented in this list by application of
Fisher’s exact test which calculates a P-value determining
the probability that the association between the genes in
the list and the database pathway were explained by
chance alone. The significance threshold of pathways was
set to 2 (derived by –log10 (P value), for P = 0.01).Quantitative real time PCR
Expression levels of specific microRNAs were analyzed by
quantitative real time PCR (qRT-PCR) using miRCURY
LNA™ microRNA PCR system according to the manufac-
turer’s protocol (Exiqon, Vedbaek, Denmark). RNA was
converted to cDNA using a universal cDNA synthesis
kit (Exiqon, Vedbaek, Denmark). cDNA samples were then
PCR amplified using SYBR Green master mix and LNA™
microRNA primers (Exiqon, Vedbaek, Denmark). Primers
targeting mmu-miR-335-5p (target sequence UCAAGAGC
AAUAACGAAAAAUGU), mmu-miR-34a (target sequence
UGGCAGUGUCUUAGCUGGUUGU), mmu-miR-21 (tar-
get sequence UAGCUUAUCAGACUGAUGUUGA) and
mmu-miR-26a (target sequence UUCAAGUAAUCCAGG
AUAGGCU) were used. Samples were run on an Applied
Biosystems International Prism 7500 instrument (Burlington,ON, Canada). The data were normalized to a U6 RNA con-
trol and relative expression was calculated using the com-
parative CT method, as previously described [60].
Gene expression experiments were completed as de-
scribed previously [61]. Briefly, 4 to 5 μg of total RNA from
the right mouse lung was reversely transcribed with oligo
(dT) primer using Superscript™ III RNase H-Reverse Tran-
scriptase (Invitrogen, Carlsbad, CA, USA) to make cDNA.
Quantitative real-time PCR assays were performed using
the Applied Biosystems International Prism 7500 Sequence
Detection System and assays on demand for Igf1 (Insulin-
like growth factor 1, Mn00439561_m1), Igfbp3 (Insulin-like
growth factor-binding protein 3, Mn01187817_m1), Igfbp4
(Mn00516037_m1) and Igfbp5 (Mn00494922_m1), with
Ataxin 10 (Atxn10, assay Mm00450332_m1) used as the
reference gene. Relative expression was calculated using
the comparative CT method [60] and differences between
bleomycin treated and control animals were assessed by
Student’s t-tests.
In-situ hybridization
In situ hybridization was performed using miRCURY
LNA™ ISH Optimization Kit (Exiqon, Vedbaek, Denmark)
according to the manufacturer’s instructions. Briefly, lung
sections were incubated with Proteinase K to expose
microRNAs, and hybridized with double-digoxigenin la-
beled probes against miR-21 and miR-34a (Exiqon,
Vedbaek, Denmark). Digoxigenin-labeled probes were
detected with sheep anti-digoxigenin-alkaline phosphat-
ase antibody (Roche, Mississauga, ON, Cnada) and visu-
alized with nitro blue tetrazolium chloride/5-bromo-4-
chloro-3-indolyl phosphate ready-to-use tablets (Roche,
Mississauga, ON, Canada). Slides were counterstained
with Nuclear Fast Red (Sigma, Oakville, ON, Canada).
Scoring of 10 complete fields randomly selected throughout
each lung was performed by a user blind to the treatment
and presented as the average number of positively stained
cell/mm2. Differences between groups were assessed with
Student’s t-test.
Immunohistochemistry
Staining was completed as previously described [62,63]
using antibodies against Igf1 (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA, sc-9013, dilution 1:50) and F4/
80 (Serotec, Raleigh, NC, USA, MCA497R, dilution 1:300).
Sections were developed using Vectastain ABC-Alkaline
phosphatase kit (Vector Laboratories, Burlington, ON,
Canada) and Vector Red Alkaline phosphatase substrate
kit (Vector Laboratories, Burlington, ON, Canada). Slides
were counterstained with methyl green. Blind scoring of 10
complete fields randomly selected throughout each lung
was performed and presented as the average number of
positively stained cell/mm2. Differences between groups
were assessed with Student’s t-test.
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Additional file 1: F4/80 positive cells in bleomycin treated and
control C57BL/6J mice. Immunohistochemistry of F4/80 in (A)
bleomycin treated lungs and (B) control lungs. Magnification 400×, insert
magnification 1000×. (C) Quantification of F4/80 positive cells per mm2
lung tissue ± standard deviation of n=7-13 mice per group.
* indicates a significant difference between groups, p < 0.0005.
Additional file 2: Pathways significantly represented within
differentially expressed genes that were not predicted to be
regulated by microRNA.
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